Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.
2.

FVC variability in patients with IPF and role of 6-min walk test to predict further change.

Nathan SD, Yang M, Morgenthien EA, Stauffer JL.

Eur Respir J. 2020 Feb 6. pii: 1902151. doi: 10.1183/13993003.02151-2019. [Epub ahead of print] No abstract available.

PMID:
32029447
3.

Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis.

LaCamera PP, Limb SL, Haselkorn T, Morgenthien EA, Stauffer JL, Wencel ML.

Chron Respir Dis. 2019 Jan-Dec;16:1479973119879678. doi: 10.1177/1479973119879678.

4.

Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Glassberg MK, Nathan SD, Lin CY, Morgenthien EA, Stauffer JL, Chou W, Noble PW.

Adv Ther. 2019 Oct;36(10):2927-2929. doi: 10.1007/s12325-019-01082-6.

5.

Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Glassberg MK, Nathan SD, Lin CY, Morgenthien EA, Stauffer JL, Chou W, Noble PW.

Adv Ther. 2019 Oct;36(10):2910-2926. doi: 10.1007/s12325-019-01052-y. Epub 2019 Aug 10. Erratum in: Adv Ther. 2019 Sep 9;:.

6.

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.

Nathan SD, Costabel U, Albera C, Behr J, Wuyts WA, Kirchgaessler KU, Stauffer JL, Morgenthien E, Chou W, Limb SL, Noble PW.

Respir Med. 2019 Jul;153:44-51. doi: 10.1016/j.rmed.2019.04.016. Epub 2019 Apr 24.

7.

Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.

van Cleemput J, Sonaglioni A, Wuyts WA, Bengus M, Stauffer JL, Harari S.

Adv Ther. 2019 Feb;36(2):298-317. doi: 10.1007/s12325-018-0857-z. Epub 2018 Dec 15. Review.

8.

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.

Cottin V, Koschel D, Günther A, Albera C, Azuma A, Sköld CM, Tomassetti S, Hormel P, Stauffer JL, Strombom I, Kirchgaessler KU, Maher TM.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00084-2018. doi: 10.1183/23120541.00084-2018. eCollection 2018 Oct.

9.

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.

Flaherty KR, Fell CD, Huggins JT, Nunes H, Sussman R, Valenzuela C, Petzinger U, Stauffer JL, Gilberg F, Bengus M, Wijsenbeek M.

Eur Respir J. 2018 Aug 2;52(2). pii: 1800230. doi: 10.1183/13993003.00230-2018. Print 2018 Aug. Erratum in: Eur Respir J. 2018 Oct 4;52(4):.

10.

Real-World Practice Patterns for Prevention and Management of Potential Adverse Events with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Wencel ML, Haselkorn T, Limb SL, Stauffer JL, Morgenthien E, Raimundo K, LaCamera PP.

Pulm Ther. 2018 Jun;4(1):103-114. doi: 10.1007/s41030-018-0056-8. Epub 2018 May 29.

11.

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002).

Gotfried MH, Girod CE, Antin-Ozerkis D, Burgess T, Strombom I, Stauffer JL, Kirchgaessler KU, Padilla ML.

Pulm Ther. 2018 Jun;4(1):59-71. doi: 10.1007/s41030-018-0053-y. Epub 2018 Apr 5.

12.

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.

Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U.

Eur Respir Rev. 2017 Dec 6;26(146). pii: 170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Review.

13.

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.

Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR.

Am J Respir Crit Care Med. 2017 Sep 15;196(6):756-761. doi: 10.1164/rccm.201701-0091OC.

14.

Montelukast added to fluticasone propionate does not alter inflammation or outcomes.

Djukanović R, Wilson SJ, Moore WC, Koenig SM, Laviolette M, Bleecker ER, Davis WB, Doherty DE, Olivenstein R, Israel E, Kavuru MS, Kleerup E, Reilly DS, Yancey SW, Edwards LD, Stauffer JL, Dorinsky PM, Jarjour NN.

Respir Med. 2010 Oct;104(10):1425-35. doi: 10.1016/j.rmed.2010.04.004. Epub 2010 Aug 14.

15.

The maize (Zea mays L.) RTCS gene encodes a LOB domain protein that is a key regulator of embryonic seminal and post-embryonic shoot-borne root initiation.

Taramino G, Sauer M, Stauffer JL Jr, Multani D, Niu X, Sakai H, Hochholdinger F.

Plant J. 2007 May;50(4):649-59. Epub 2007 Apr 8.

16.

Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol.

Jarjour NN, Wilson SJ, Koenig SM, Laviolette M, Moore WC, Davis WB, Doherty DE, Hamid Q, Israel E, Kavuru MS, Ramsdell JW, Tashkin DP, Reilly DS, Yancey SW, Edwards LD, Stauffer JL, Dorinsky PM, Djukanovic R.

J Allergy Clin Immunol. 2006 Jul;118(1):44-52. Epub 2006 Jun 2.

PMID:
16815137
17.

Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control.

Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, Dorinsky PM, Nelson HS.

Chest. 2005 Oct;128(4):1910-20.

PMID:
16236835
18.

The Human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer.

Zhang Y, Lu Y, Yuan BZ, Castranova V, Shi X, Stauffer JL, Demers LM, Chen F.

Oncogene. 2005 Jul 21;24(31):4873-82.

PMID:
15897898
19.

Transbronchial biopsy with virtual CT bronchoscopy and nodal highlighting.

Hopper KD, Lucas TA, Gleeson K, Stauffer JL, Bascom R, Mauger DT, Mahraj R.

Radiology. 2001 Nov;221(2):531-6.

PMID:
11687700
20.

Do autopsies of critically ill patients reveal important findings that were clinically undetected?

Blosser SA, Zimmerman HE, Stauffer JL.

Crit Care Med. 1998 Aug;26(8):1332-6.

PMID:
9710090
21.

Intubation of critically ill patients.

Blosser SA, Stauffer JL.

Clin Chest Med. 1996 Sep;17(3):355-78. Review.

PMID:
8875001
22.

Inflammatory and fibrotic mediator release by alveolar macrophages from coal miners.

Kuhn DC, Stauffer JL, Gaydos LJ, Demers LM.

J Toxicol Environ Health. 1995 Sep;46(1):9-21.

PMID:
7666496
23.

Effects of alpha 2-agonists on intrauterine pressure and sedation in horses: comparison between detomidine, romifidine and xylazine.

Schatzmann U, Jossfck H, Stauffer JL, Goossens L.

Zentralbl Veterinarmed A. 1994 Sep;41(7):523-9.

PMID:
8831268
24.

Survival following mechanical ventilation for acute respiratory failure in adult men.

Stauffer JL, Fayter NA, Graves B, Cromb M, Lynch JC, Goebel P.

Chest. 1993 Oct;104(4):1222-9.

PMID:
8404197
25.

Characterization of alveolar macrophage eicosanoid production in a non-human primate model of mineral dust exposure.

Kuhn DC, Griffith JW, Stauffer JL, Riling S, Demers LM.

Prostaglandins. 1993 Sep;46(3):207-20.

PMID:
8234829
26.

An inhibitor of thromboxane production attenuates tumor necrosis factor release by activated human alveolar macrophages.

Kuhn DC, Stauffer JL, Gaydos LJ, Lacey SL, Demers LM.

Prostaglandins. 1993 Sep;46(3):195-205.

PMID:
8234828
27.

Endobronchial streptokinase for relief of tracheobronchial obstruction by blood clots.

Maxwell SL, Stauffer JL.

Chest. 1992 Jun;101(6):1738-9. No abstract available.

PMID:
1600809
28.

Medical management of the airway.

Stauffer JL.

Clin Chest Med. 1991 Sep;12(3):449-82. Review.

PMID:
1934949
29.
30.

Morphology of the uvula in obstructive sleep apnea.

Stauffer JL, Buick MK, Bixler EO, Sharkey FE, Abt AB, Manders EK, Kales A, Cadieux RJ, Barry JD, Zwillich CW.

Am Rev Respir Dis. 1989 Sep;140(3):724-8.

PMID:
2782743
31.

Cardiac dysrhythmias during anesthesia for cervical decompression in the dog.

Stauffer JL, Gleed RD, Short CE, Erb HN, Schukken YH.

Am J Vet Res. 1988 Jul;49(7):1143-6.

PMID:
3421536
32.

Pharyngeal size and resistance in obstructive sleep apnea.

Stauffer JL, Zwillich CW, Cadieux RJ, Bixler EO, Kales A, Varano LA, White DP.

Am Rev Respir Dis. 1987 Sep;136(3):623-7.

PMID:
3631735
33.

The use of atropine to control heart rate responses during detomidine sedation in horses.

Short CE, Stauffer JL, Goldberg G, Vainio O.

Acta Vet Scand. 1986;27(4):548-59. No abstract available.

PMID:
3604828
34.

Bacillus cereus pleuropulmonary infection in a normal host.

Carbone JE, Stauffer JL.

West J Med. 1985 Nov;143(5):676-7. No abstract available.

35.

Sleep apnea in amyloidosis.

Carbone JE, Barker D, Stauffer JL.

Chest. 1985 Mar;87(3):401-3.

PMID:
3971769
36.

Conjunctivitis from nasal CPAP apparatus.

Stauffer JL, Fayter N, MacLurg BJ.

Chest. 1984 Nov;86(5):802. No abstract available.

PMID:
6386364
37.

The pH of ascitic fluid in the diagnosis of spontaneous bacterial peritonitis in alcoholic cirrhosis.

Gitlin N, Stauffer JL, Silvestri RC.

Hepatology. 1982 Jul-Aug;2(4):408-11.

PMID:
6807793
38.
39.

Plasma cell granuloma of the lung: endobronchial presentation and absence of response to radiation therapy.

Mehta J, Desphande S, Stauffer JL, Stanford R, Fernandez E.

South Med J. 1980 Sep;73(9):1198-1201.

PMID:
7414377
40.

Cellular content of the normal rabbit pleural space.

Stauffer JL, Potts DE, Sahn SA.

Acta Cytol. 1978 Nov-Dec;22(6):570-4.

PMID:
367029
41.

Cleft tongue and ulceration of hard palate: complications of oral intubation.

Stauffer JL, Petty TL.

Chest. 1978 Sep;74(3):317-8.

PMID:
688796
42.

Accidental intubation of the pyriform sinus. A complication of "roadside" resuscitation.

Stauffer JL, Petty TL.

JAMA. 1977 May 23;237(21):2324-5. No abstract available.

PMID:
576927
43.

Bacterial endocarditis due to actinobacillus actinomycetemcomitans in a patient with a prosthetic aortic valve.

Stauffer JL, Goldman MJ.

Calif Med. 1972 Aug;117(2):59-63. No abstract available.

Supplemental Content

Loading ...
Support Center